Clinicopathological details of the patient cohort
| Variable | Mean (median; range) or n (%) |
|---|---|
| Age at surgery (years) | 64.8 (65.1; 43.7–76.7) |
| Preoperative PSA (ng/mL) | 9.5 (8.8; 1.0–24) |
| Follow-up time (years) | 3.1 (2.8; 0.1–4.1) |
| Gleason grade | |
| <7 | 26 (24%) |
| 7 | 77 (70%) |
| 3+4 | 61 (55%) |
| 4+3 | 16 (15%) |
| >7 | 7 (6%) |
| T-stage | |
| pT2 | 60 (55%) |
| pT3a | 40 (36%) |
| pT3b | 10 (9%) |
| Extracapsular perineural invasion | |
| Yes | 40 (36%) |
| No | 70 (64%) |
| Extracapsular extension | |
| Yes | 48 (44%) |
| No | 61 (56%) |
| Positive surgical margins | |
| Yes | 64 (58%) |
| No | 46 (42%) |
| Biochemical recurrence | |
| Yes | 24 (22%) |
| No | 86 (78%) |
PSA, prostate-specific antigen.